Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine

BMC Complementary and Alternative Medicine

Jia Zheng¹  Zhixin Wang¹  Fan Ping¹  Huabing Zhang¹  Miao Yu¹  Wenhui Li¹  Ming Li¹  Xinhua Xiao¹  Qian Zhang¹ 

[1] Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

关键词: GnRH;    Gene expression;    Digestive tract;    Diabetes;   

Others  :  1220095
DOI  :  10.1186/1472-6882-14-188

 received in 2013-11-20, accepted in 2014-06-03,  发布年份 2014

【 摘 要 】

Background

Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut. Therefore, the exact underlying mechanism for berberine is still unknown. In this study, we investigated the effect of berberine on glucose metabolism in diabetic rats and tested the hypothesis that berberine acts directly in the terminal ileums.

Methods

Rats were divided into a control group, diabetic group (DM), low dose of berberine group (BerL) and high dose of berberine group (BerH). Ileum samples were analyzed using a Roche NimbleGen mRNA array, qPCR and immunohistochemistry.

Results

We found that 8 weeks of treatment with berberine significantly decreased fasting blood glucose levels. An oral glucose tolerance test (OGTT) showed that blood glucose was significantly reduced in the BerL and BerH groups before and at 30 min, 60 min and 120 min after oral glucose administration. Plasma postprandial glucagon-like peptide-1 (GLP-1) levels were increased in the berberine-treated groups. The ileum from the BerH group had 2112 genes with significantly changed expression (780 increased, 1332 decreased). KEGG pathway analyses indicated that all differentially expressed genes included 9 KEGG pathways. The top two pathways were the MAPK signaling pathway and the GnRH signaling pathway. Q-RT-PCR and immunohistochemistry verified that glucagon-like peptide 1 receptor (Glp1r) and mitogen activated protein kinase 10 (Mapk10) were significantly up-regulated, in contrast, gonadotropin releasing hormone receptor (Gnrhr) and gonadotropin-releasing hormone 1 (Gnrh1) were down-regulated in the BerH group.

Conclusion

Our data suggest that berberine can improve blood glucose levels in diabetic rats. The mechanisms involved may be in the MAPK and GnRh-Glp-1 pathways in the ileum.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes. Diabetes Cares 2004, 27:1047-1053.
• [2]Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, Li F, Tang J, Chen M, Chen J: Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007, 56:405-412.
• [3]Yin J, Gao Z, Liu D, Liu Z, Ye Y: Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol 2008, 294:E148-E156.
• [4]Turner N, Li YJ, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM: Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57:1414-1418.
• [5]Wang YW, Wang YP, Zhang H, Kong WJ, Li YH, Liu F, Gao RM, Liu T, Jiang JD, Song DQ: Synthesis and biological evalutation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg Med Chem Lett 2009, 9:6004-6008.
• [6]Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM: A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000, 49:1390-1394.
• [7]Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY: Dose conversion among different animals and healthy volunteers in pharmacological study. Chinese J Clinical Pharmacol Therap 2004, 9:1069-1072.
• [8]Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: database for annotation, visualization, and intrgrated discovery. Genome Biol 2003, 4:P3. BioMed Central Full Text
• [9]Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempocki RA: Identifying biological themes within lists of genes with EASE. Genome Biol 2003, 4:R70. BioMed Central Full Text
• [10]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
• [11]Heeckt PF, Klein D, Beger HG: Short-bowel syndrome-surgical treatment with long-term benefit? Langenbecks Arch Surg 2000, 385:50-56.
• [12]Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB: Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
• [13]Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J: Effects of berberine on glucose metabolism in vitro. Metabolism 2002, 51:1439-1443.
• [14]Tang LQ, Wei W, Chen LM, Liu S: Effects of berberine on diabetes induced by alloxan and a high fat/highcholesterol diet in rats. J Ethnopharmacol 2006, 108:109-115.
• [15]Gao CR, Zhang JG, Huang QL: Experimental study on berberin raised insulin sensitivity in insulin resistance rat Models. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997, 17:162-164. Chinese
• [16]Zhang Q, Xiao X, Feng K, Wang T, Li W, Yuan T, Sun Q, Xiang H, Wang H: Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evidence-based Complement Alter Med 2011. doi:10.1155/2011/924851. Epub 2010 Sep 26.
• [17]Burcelin R, Cani PD, Knauf C: Glucagon-like peptide-1 and energy homeostasis. J Nutri 2007, 137:2534S-2538S.
• [18]Schmidtler J, Schepp W, Janczewska I, Weigert N, Furlinger C, Schusdziarra V, Classen M: GLP-1-(7-36) amide -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function. Am J Physiol 1991, 260:940-950.
• [19]Ranganath LR: Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 2008, 61:401-409.
• [20]Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, Wang P, Xie L, Wang GJ: Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocronol 2009, 200:159-165.
• [21]Feng Y, Li Y, Chen X, Lin X, Yang Y, Cai H, Lv Z, Cao M, Li K, Xu J, Li S, Jia Y: Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. Phytotheapyr Res 2013, 27:1564-1571.
• [22]Shan C, Yang J, Kong Y, Wang X, Zheng M, Xu Y, Wang Y, Ren H, Chang B, Chen L: Alteration of intestinal barrier and GLP2 secretion in berberine treated type 2 diabetic rats. J Endocrinol 2013, 218:255-262.
• [23]Camilleri M, Vazguez-Rogue M, Iturrino J, Boldingh A, Burton D, McKinzie S, Wong BS, Rao AS, Kenny E, Mansson M, Zinsmeister AR: Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastroint Liver Physiol 2012, 303:G120-G128.
• [24]Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S: p38 mitogen-activated protein kinase is activated and linked to TNF- alpha signaling in inflammatory bowel disease. J Immunol 2002, 168:5342-5351.
• [25]Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M: Inhibition of p38MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004, 18:1550-1552.
• [26]Huang W, Yao B, Sun L, Pu R, Wang L, Zhang R: Immunohistichemical and in situ hybridization of gonadotropin releasing hormone (GnRH) and its receptor mRNA in rat digestive tract. Life Sci 2001, 68:1727-1734.
• [27]Yao B, Huang W, Huang Y, Chui Y, Wang Y, Li H, Pu R, Wan L, Zhang R: A study on the localization and distribution of GnRH and its receptor in rat submaxillary glands by immunohistochemical, in situ hybridization and RT-PCR. Life Sci 2003, 72:2895-2904.
• [28]Gao B, Ji QH, Huang WQ: Immunihistichemical localization of glucagon, gonadotropin releasing hormone receptor in rat digestive tract. Chinese J Anatomy 2004, 27:372-379.
• [29]Smith MR: Ostroporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol 2004, 172:S52-S57.
• [30]Palomba S, Russo T, Orio JF, Sammartino A, Sbano FM, Nappi C, Colao A, Mastrantonio P, Lombardi G, Zullo F: Lipid, glucose and lomocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod 2004, 19:415-421.
• [31]Ansari MA, Dhar M, Spieker S, Bakht N, Rahman AM, Moore WV, Jacobson JD: Modulation of diabetes with gonadotropin-releasing hromine antagonists in the nonobese mouse model of autoimmune diabetes. Endocrinology 2004, 145:337-342.
• [32]Klier M, Schusdziarra V, Pfeiffer EF: Effect of luteinizing hormone-releasing hormone upon insulin release form rat islets in vitro. FEBS Lett 1980, 121:363-365.